Antibodies for IL-17C
The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
1. A method for treating a subject suffering from an inflammatory disorder, comprising administering to said subject an effective amount of an antibody or antibody fragment comprising
a) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 7, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 8, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 9, a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 13, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 14 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 15, or
b) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 21, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 22, a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 26, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 27 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 28.
2. The method of claim 1 , wherein said antibody or antibody fragment is specific for human IL-17C.
3. The method of claim 2 , wherein said antibody or antibody fragment is specific for human IL-17C, cynomolgus IL-17C and mouse IL-17C.
4. The method of claim 1 , wherein said antibody or antibody fragment is a human, humanized or chimeric antibody or antibody fragment.
5. The method of claim 1 , wherein said antibody or antibody fragment comprises the sequences set forth in SEQ ID NO: 17 and SEQ ID NO: 16.
6. The method of claim 1 , wherein said antibody or antibody fragment comprises the sequences set forth in SEQ ID NO: 30 and SEQ ID NO: 29.
7. The method of claim 1 , wherein said antibody or antibody fragment is an isolated antibody or antibody fragment.
8. The method of claim 1 , wherein said antibody or antibody fragment is a recombinant antibody or antibody fragment.
9. A method for treating a subject suffering from an inflammatory disorder, comprising administering to said subject an effective amount of a pharmaceutical composition comprising an antibody or antibody fragment comprising
a) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 7, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 8, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 9, a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 13, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 14 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 15, or
b) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 21, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 22, a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 26, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 27 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 28; and
a pharmaceutically acceptable carrier or excipient.
10. The method of claim 9 , wherein said antibody or antibody fragment is specific for human IL-17C.
11. The method of claim 10 , wherein said antibody or antibody fragment is specific for human IL-17C, cynomolgus IL-17C and mouse IL-17C.
12. The method of claim 9 , wherein said antibody or antibody fragment is a human, humanized or chimeric antibody or antibody fragment.
13. The method of claim 9 , wherein said antibody or antibody fragment comprises the sequences set forth in SEQ ID NO: 17 and SEQ ID NO: 16.
14. The method of claim 9 , wherein said antibody or antibody fragment comprises the sequences set forth in SEQ ID NO: 30 and SEQ ID NO: 29.
15. The method of claim 9 , wherein said antibody or antibody fragment is an isolated antibody or antibody fragment.
16. The method of claim 9 , wherein said antibody or antibody fragment is a recombinant antibody or antibody fragment.
17. A method for treating a subject suffering from an inflammatory disorder, comprising administering to said subject an effective amount of an antibody or antibody fragment comprising
(a) the sequences set forth in SEQ ID NO: 17 and SEQ ID NO: 16; or
(b) the sequences set forth in SEQ ID NO: 30 and SEQ ID NO: 29.